Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Oslo, Norway, 22 June 2021 Nordic Nanovector ASA (OSE: NANOV) announces encouraging initial results from the LYMRIT 37-05 Phase 1 trial investigating Betalutin® ([177]Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for stem cell transplantation. The initial results from the completed Phase I study (n=16 treated with Betalutin®) show that Betalutin® was well tolerated, with a good safety profile consistent with all previous studies with Betalutin®. As reported previously, a single, reversible dose-limiting toxicity (